Full Press Release Details
PellePharm Announces Topline Results From Phase 2 Study Of Topical Patidegib In Gorlin Syndrome Basal Cell Carcinomas And Third Closing Of A $20 Million Series B Financing.
BBIO
PellePharm Announces Topline Results From Phase 2 Study Of Topical Patidegib In Gorlin Syndrome Basal Cell Carcinomas And Third Closing Of A $20 Million Series B Financing
Key Takeaway: PellePharm Announces Topline Results From Phase 2 Study Of Topical Patidegib In Gorlin Syndrome Basal Cell Carcinomas And Third Closing Of A $20 Million Series B Financing
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis